Corporate Events

Towa Pharmaceutical Co., Ltd. announced the following changes in directors as resolved at its Ordinary General Meeting of Shareholders and Board of Directors meeting held on June 25, 2025. Name: Osamu Uchikawa: Current title: Director. New title: Executive Managing Director.

Towa Pharmaceutical Co., Ltd., Board Meeting, Jun 25, 2025. Agenda: To consider the disposal of treasury shares as detailed below; to consider the introduction of a restricted stock compensation plan for the Company's directors excluding outside directors, Audit and Supervisory Committee Members, and directors subject to medium- to long-term performance-based stock price-linked compensation.

Towa Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025

Towa Pharmaceutical Co., Ltd. expected to report Q1 2026 results on August 8, 2025. This event was calculated by S&P Global (Created on May 21, 2025).

Towa Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the six months ending September 30, 2025 and full year ending March 31, 2026. For the six months, the company expects net sales of JPY 134,500 million, operating profit of JPY 12,000 million profit attributable to owners of parent of JPY 8,000 million and earnings per share of JPY 162.52. For the full year, the company expects net sales of JPY 280,000 million, operating profit of JPY 27,000 million, profit attributable to owners of parent of JPY 17,700 million and earnings per share of JPY 359.57.

Towa Pharmaceutical Co., Ltd. provided year end dividend guidance for the fiscal year ending March 31, 2026. For the year end, the company expects dividend of JPY 40.00 per share against JPY 40.00 per share a year ago.

Towa Pharmaceutical Co., Ltd. announced the year end dividend of JPY 40.00 per share for the fiscal year ended March 31, 2025, payable on June 26, 2025 against JPY 30.00 per share a year ago. provided second quarter dividend guidance for the fiscal year ending March 31, 2026. For the quarter, the company expects dividend of JPY 40.00 per share against JPY 30.00 per share a year ago.

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2025.

Towa Pharmaceutical Co., Ltd., Board Meeting, May 15, 2025. Agenda: To consider revise its financial objectives of the 6th Medium-term Business Plan (2024-2026) PROACTIVE.

Towa Pharmaceutical Co., Ltd. revised earnings guidance for the year ending March 31, 2025. Net sales JPY 259,500 million, Operating profit JPY 23,200 million, Profit attributable to owners of parent JPY 18,900 million and Earnings per share JPY 383.95 against previous guidance of Net sales of JPY 262,100 million, operating profit of JPY 23,300 million, profit attributable to owners of parent of JPY 15,000 million and basic profit per share of JPY 304.72.

Towa Pharmaceutical Co., Ltd., Q4 2025 Earnings Call, May 20, 2025

Towa Pharmaceutical Co., Ltd., Board Meeting, Mar 17, 2025. Agenda: To consider the Notice of Partial Revision of the Basic Policy for the Development of an Internal Control System.

Towa Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025

Towa Pharmaceutical Co., Ltd. provided dividend guidance of JPY 40.00 per share of the Year ending March 31, 2025 as compared to JPY 30.00 per share paid a year ago.

Towa Pharmaceutical Co., Ltd. declared second quarter dividend of JPY 30.00 per share of the Year ending March 31, 2025.

Towa Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected Net sales of JPY 262,100 million, operating profit of JPY 23,300 million, profit attributable to owners of parent of JPY 15,000 million and basic profit per share of JPY 304.72.

Towa Pharmaceutical Co., Ltd., Board Meeting, Feb 13, 2025. Agenda: To consider and approve Revision of Dividend Forecasts.

Towa Pharmaceutical Co., Ltd. expected to report Fiscal Year 2025 results on May 20, 2025. This event was calculated by S&P Global (Created on April 30, 2025).

Towa Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 13, 2025

Towa Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Mar-28-2025

Towa Pharmaceutical Co., Ltd. revised earnings guidance for the first half ended September 30, 2024 and full year ending March 31, 2025. for the half year, the company expects net sales of JPY 123,400 million against JPY 122,800 expected previously, operating profit of JPY 10,500 million compared to previous guidance of JPY 6,800 million, profit attributable to owners of parent of JPY 6,500 million compared to previous guidance of JPY 4,100 million and earnings per share of JPY 132.05 compared to previous guidance of JPY 83.30 per share. for the year, the company expects net sales of JPY 262,100 million against JPY 261,500 expected previously, operating profit of JPY 23,300 million compared to previous guidance of JPY 19,600 million, profit attributable to owners of parent of JPY 15,000 million compared to previous guidance of JPY 12,600 million and earnings per share of JPY 304.72 compared to previous guidance of JPY 255.99 per share. Reason for the revision: With regard to the consolidated financial forecasts for the first half of the fiscal year ending March 31, 2025, net sales are expected to exceed the previous forecast, mainly due to an increase in sales in overseas segment due to yen conversion at the yen depreciation rate than the assumed exchange rate. Operating profit is expected to exceed the previous forecast mainly due to the fact that R&D expenses are lower than expected. Ordinary profit and profit attributable to owners of parent are expected to exceed the previous forecast, mainly due to an increase in operating profit, 1.4 billion yen in foreign exchange gains, and a loss of 1.2 billion yen on valuation of derivatives. The consolidated financial forecasts for the second half of the fiscal year ending March 31, 2025 has not been changed from the previous forecast, and the full-year consolidated financial forecast only incorporates revisions to this first-half consolidated financial forecast.

Towa Pharmaceutical Co., Ltd., Q2 2025 Earnings Call, Nov 15, 2024

Towa Pharmaceutical Co., Ltd. announced that on September 30, 2024, a settlement was reached in a lawsuit filed by Eagle Pharmaceuticals, Inc. and SymBio Pharmaceuticals Limited against the Company in the Tokyo District Court on December 16, 2022, seeking an injunction against patent infringement and compensation for damage, as detailed below. 1. Background from the filing of the lawsuit to the settlement The Lawsuit was filed by the two plaintiffs against the Company in the Tokyo District Court on December 16, 2022 regarding BENDAMUSTINE HYDROCHLORIDE INTRAVENOUS INFUSION 25mg/1mL "TOWA" and BENDAMUSTINE HYDROCHLORIDE INTRAVENOUS INFUSION 100mg/4mL "TOWA", which were launched in June 2022. A court settlement has now been reached in this Lawsuit. 2. Outline of the settlement counterparties: Plaintiff (1): Eagle Pharmaceuticals, Inc. 50 Tice Blvd, Suite 315, Woodcliff Lake, NJ 07677, U.S.A. Michael Graves, Interim Executive Chairman of the Board Interim Principal Executive Officer. Plaintiff (2): SymBio Pharmaceuticals Limited Toranomon Towers Office, 7th floor, 4-1-28 Toranomon, Minato-ku, Tokyo, Japan Fuminori Yoshida, Representative Director. Settlement details It will refrain from disclosing the details of the settlement since the settlement agreement includes a non-disclosure clause.

Towa Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 12, 2024